Get the Stockscreener App
5.09
3.25%
0.16
After Hours:
5.07
-0.02
-0.39%
Verastem Inc stock is traded at $5.09, with a volume of 2.41M.
It is up +3.25% in the last 24 hours and down -12.69% over the past month.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
See More
Previous Close:
$4.93
Open:
$5.01
24h Volume:
2.41M
Relative Volume:
1.29
Market Cap:
$447.08M
Revenue:
$30.91M
Net Income/Loss:
$-209.47M
P/E Ratio:
-1.5295
EPS:
-3.3279
Net Cash Flow:
$-147.13M
1W Performance:
-8.45%
1M Performance:
-12.69%
6M Performance:
-40.88%
1Y Performance:
-22.53%
1-Day Range:
$4.97
$5.22
1-Week Range:
$4.86
$5.97
52-Week Range:
$4.01
$11.24
Verastem Inc Stock (VSTM) Company Profile
Name
Verastem Inc
Sector
Industry
Phone
(781) 292-4200
Address
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
5.09 | 433.03M | 30.91M | -209.47M | -147.13M | -3.3279 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| Feb-04-26 | Initiated | H.C. Wainwright | Buy |
| Oct-16-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-10-25 | Initiated | Jefferies | Buy |
| Mar-24-25 | Reiterated | H.C. Wainwright | Buy |
| Dec-31-24 | Reiterated | BTIG Research | Buy |
| Sep-30-24 | Initiated | Guggenheim | Buy |
| Nov-21-23 | Resumed | BTIG Research | Buy |
| Sep-27-23 | Initiated | B. Riley Securities | Buy |
| Jun-15-23 | Upgrade | Mizuho | Neutral → Buy |
| Sep-07-22 | Resumed | Alliance Global Partners | Buy |
| Apr-29-22 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-14-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-09-22 | Initiated | Truist | Buy |
| Jul-01-21 | Initiated | Alliance Global Partners | Buy |
| May-24-21 | Upgrade | BTIG Research | Neutral → Buy |
| Jun-20-19 | Downgrade | BTIG Research | Buy → Neutral |
| May-10-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-13-18 | Initiated | BTIG Research | Buy |
| May-02-18 | Initiated | Seaport Global Securities | Buy |
| Mar-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-07-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-17 | Initiated | Oppenheimer | Outperform |
| Mar-24-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-29-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Sep-29-15 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-29-15 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-15 | Downgrade | Raymond James | Strong Buy → Outperform |
| Sep-28-15 | Downgrade | Mizuho | Buy → Neutral |
| Sep-28-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| May-12-15 | Reiterated | UBS | Buy |
| Apr-08-15 | Initiated | H.C. Wainwright | Buy |
| Jan-23-15 | Reiterated | ROTH Capital | Buy |
| Jul-08-14 | Resumed | Oppenheimer | Perform |
| Feb-11-14 | Initiated | Mizuho | Buy |
View All
Verastem Inc Stock (VSTM) Latest News
Verastem (VSTM) CFO receives 57-share stock award in Form 4 - Stock Titan
Market Moves: What analysts say about Verastem Inc stock2026 Earnings Surprises & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Verastem: Maintaining "Buy" As 1st Half 2026 Catalysts In Play (NASDAQ:VSTM) - Seeking Alpha
Verastem Oncology drops despite Q3 double beat - MSN
AACR Meeting spotlights Verastem, Inc. progress on oral KRAS G12D inhibitor - Traders Union
FinancialContentVerastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 - FinancialContent
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers - Yahoo Finance
Foresite Capital Management VI LLC Has $23.09 Million Holdings in Verastem, Inc. $VSTM - MarketBeat
Verastem (NASDAQ:VSTM) Stock Rating Upgraded by BTIG Research - MarketBeat
Discipline and Rules-Based Execution in VSTM Response - Stock Traders Daily
Why did Verastem stock jump after-hours despite an earnings miss? - MSN
Verastem (VSTM) Q4 2025 Earnings Call Transcript - AOL.com
Verastem's (VSTM) Buy Rating Reaffirmed at BTIG Research - MarketBeat
Verastem stock initiated at Buy by BTIG with $19 price target - Investing.com Australia
Verastem stock initiated at Buy by BTIG with $19 price target By Investing.com - Investing.com India
Wall Street Analysts See a 159.31% Upside in Verastem (VSTM): Can the Stock Really Move This High? - Yahoo Finance
Verastem (VSTM) reports Q4 loss, beats revenue estimates - MSN
Jefferies Financial Group Inc. Increases Stake in Verastem, Inc. $VSTM - MarketBeat
Earnings call transcript: Verastem’s Q4 2025 results highlight oncology growth - Investing.com Nigeria
Verastem Earnings Call: Early Momentum, Long Runway Risks - TipRanks
Verastem (NASDAQ:VSTM) Raised to Hold at Wall Street Zen - MarketBeat
Verastem, Inc. (NASDAQ:VSTM) Q4 2025 Earnings Call Transcript - Insider Monkey
Jefferies Maintains Buy on Verastem, Inc. (VSTM) March 2026 - Meyka
Verastem (VSTM) Q4 Revenue Debut Highlights Ongoing Losses And Tests Bullish Profitability Timeline - simplywall.st
Verastem 2025 Financial Results: Q4 and Annual Revenue & LossNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? - Stocktwits
Jefferies reiterates Verastem stock rating on launch progress By Investing.com - Investing.com Canada
Verastem, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Verastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and Financial Challenges - GuruFocus
Verastem Q4 2025 Earnings Call Transcript - MarketBeat
Verastem Q4 Earnings Call Highlights - MarketBeat
Verastem: Fourth Quarter Financial Results Overview - Bitget
Verastem (VSTM) Reports Strong Q4 2025 Earnings and Progress in Clinical Trials - GuruFocus
Key Developments for Verastem (VSTM) in 2026 Clinical Trials - GuruFocus
Verastem Highlights AVMAPKI FAKZYNJA Strategy and Pipeline Risks - TipRanks
Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Verastem (VSTM) Reports Strong Revenue and Advances Cancer Treat - GuruFocus
Verastem (NASDAQ:VSTM) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Verastem: Q4 Earnings Snapshot - KVUE
Verastem, Inc. releases Q4 and year end 2025 results with business update - Traders Union
Verastem (VSTM) shares updated March 4, 2026 corporate presentation - Stock Titan
Earnings Summary: Verastem Q4 - Benzinga
Verastem (NASDAQ: VSTM) grows LGSOC launch and advances KRAS G12D programs - Stock Titan
Verastem, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Verastem Inc Stock (VSTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):